buyWeak
Robert James Wills bought $28k of ONCT
director at Oncternal Therapeutics, Inc.. 3,086 shares at an average of $8.96, traded Apr 8, 2024, filed Apr 10, 2024.
Conviction score
31Value
$28k
3,086 shares
Holdings after
10,000
+45% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +5Trade size$28k at market
- +6Relative to holdingsHoldings up 45%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-24-005283, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 8, 2024 | POpen-market purchase Common Stock | +3,086 | $8.96 | $28k | 10,000 | Apr 10, 2024 |
Related signals
Other insiders at Oncternal Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | ONCTbuy Oncternal Therapeutics, Inc. | Robert James Wills director | $59k 6,914 shares | - | |
| 23Weak | ONCTbuy Oncternal Therapeutics, Inc. | David F Hale director | $8,859 980 shares | - | |
| 35Weak | ONCTsell Oncternal Therapeutics, Inc. | Robert James Wills director | $8,859 980 shares | -100% | |
| 21Weak | ONCTbuy Oncternal Therapeutics, Inc. | Gunnar F. Kaufmann Chief Scientific Officer | $9,824 28,000 shares | +42% | |
| 56Moderate | Oncternal Therapeutics, Inc. | James B Breitmeyer Chief Executive Officer | $44k 150,000 shares | +322% | |
| 36Weak | Oncternal Therapeutics, Inc. | Chase C. Leavitt General Counsel/Secretary | $7,250 25,000 shares | +31% | |
| 43Moderate | Oncternal Therapeutics, Inc. | Richard G Vincent Chief Financial Officer | $8,961 30,000 shares | +24% | |
| 33Weak | Oncternal Therapeutics, Inc. | Salim Yazji Chief Medical Officer | $7,200 25,000 shares | +18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.